By
Drug Target Review2024-04-03T15:00:49
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2026-06-24T13:00:00 2026-06-24T14:00:00
Sponsored by HUB Organoids
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2024-02-01T12:06:43
Sponsored by Leica Microsystems
2026-06-02T15:00:00 2026-06-02T16:00:00
Sponsored by Danaher Life Sciences
Site powered by Webvision Cloud